Na^+^/K^+^ adenosine triphosphatases (sodium/potassium pumps) are P-type cation transport proteins that establish and maintain electrochemical gradients for Na^+^ and K^+^ across the plasma membrane. Mutations in the α3 catalytic subunit, encoded by *ATP1A3*, which in the nervous system is exclusively expressed in neurons, are associated with at least 3 distinct, yet overlapping, neurologic syndromes: rapid-onset dystonia parkinsonism (RDP); alternating hemiplegia of childhood (AHC); and cerebellar ataxia, areflexia, pes cavus, optic atrophy, and sensorineural hearing loss (CAPOS). From the past descriptions of each entity, distinct phenotypes have emerged, demonstrating that classic AHC, classic RDP, and CAPOS syndrome constitute clinical prototypes in a continuous and still expanding phenotypic spectrum of *ATP1A3*-related disorders.

In June of 2014, an international consortium of experts consisting of neurologists, epileptologists, clinical geneticists, genetic counselors, physiatrists, physical therapists, psychologists, basic scientists, and foundation representatives convened in Minneapolis, MN, in conjunction with the Alternating Hemiplegia of Childhood Foundation (AHCF) International Family Meeting. A series of quarterly teleconferences performed in the year preceding the conference, including representatives from the AHCF parent advisory board and supplemented by online queries to parents via online discussion boards, were used to identify key issues and points of concern from the parent/caregiver perspective. An initial expert panel discussion and multidisciplinary workshop were followed by the selection of a task force assigned to specific key areas to further refine and revise materials over the course of the subsequent 18 months. The following article serves as a research conference summary initiated at the AHCF International Family Meeting.

Workshop attendees focused efforts on the following aims: (1) to reach consensus on an expanded diagnostic paradigm for identifying patients with an *ATP1A3*-related neurologic disorder to supplement existing syndrome-based diagnostic criteria; (2) to develop standardized definitions for types of episodic manifestations associated with AHC, the most complex of the *ATP1A3*-related neurologic phenotypes and to disseminate these among families; (3) to create initial clinical recommendations for recurrent issues facing families and medical care providers; (4) to review deaths in the AHCF database to guide future efforts in identifying at-risk subjects and potential preventative measures; and (5) to identify critical gaps where the AHC research community most needs to focus national and international efforts. The primary goal of these efforts is to promote additional reviews and discussions among the broader international community of clinicians, scientists, and family support organizations in anticipation of the robust infrastructure needed for future collaborative clinical studies and trials. In particular, natural longitudinal history data are critically needed to identify end points necessary to assess the benefit of new treatments. Our work here admittedly focused on those on the more severe end of the spectrum of *ATP1A3*-related disorders within developed countries. However, *ATP1A3*-related disorders clearly affect patients of all ages, races, and ethnicities. Continued efforts to enroll patients in registries worldwide to better understand both phenotypes and outcomes remains an important goal.

CONSENSUS TOWARD AN EXPANDED NON--SYNDROME-BASED DIAGNOSTIC ALGORITHM FOR *ATP1A3*-RELATED NEUROLOGIC DISORDERS {#s1}
===============================================================================================================

Numerous publications over the past 4 decades have described and subsequently refined clinical diagnostic criteria for what are now recognized to be *ATP1A3*-related disorders, beginning with the original description of AHC in 1971^[@R1]^ followed by RDP in 1993^[@R2]^ and of CAPOS in 1996.^[@R3]^ Mutations in *ATP1A3* were identified as the genetic cause of RDP in 2004.^[@R4]^ It was not until 2012 that de novo mutations in *ATP1A3* were found in the majority of patients with AHC.^[@R5],[@R6]^ In 2014, a novel recurrent mutation in *ATP1A3* was identified in patients with CAPOS.^[@R7]^ Since then, an increasing number of atypical cases with *ATP1A3* mutations have been identified spanning the phenotypic spectrum between AHC, RDP, and CAPOS syndromes, creating controversy as to whether these disorders should be considered discrete syndromes or points along a broadly heterogeneous spectrum.^[@R8][@R9][@R13]^

The identification and description of distinct neurologic syndromes has served as a critical point of reference to help clinicians identify and study rare patient populations in the absence of a clear molecular etiology. Prior to 2004 in RDP and 2012 in AHC, expert consensus--developed clinical criteria served as the primary pathway to diagnosis. More recently, important genotype-phenotype correlations relating to individual mutations have begun to emerge in *ATP1A3*-related neurologic disorders. We await to see whether genotype-phenotype correlations hold up over time with the accrual of new patient cohorts identified in the context of an unbiased next-generation sequencing--based approach.

Members of the task force attempted to provide a more comprehensive diagnostic approach than was afforded under previous clinical criteria. This would allow for clinicians to go beyond existing core phenotypic components in identifying *ATP1A3*-related disorders. As a starting point, we compiled diagnostic criteria for AHC and RDP and clinical features of CAPOS, inclusive of previously suggested supporting features based on the available literature ([table 1](#T1){ref-type="table"}). Next, we sought consensus on a new diagnostic paradigm that focused on major and minor neurologic symptoms or signs that broadly supported an association with mutations in *ATP1A3* in the absence of a context of a specific syndrome ([table 2](#T2){ref-type="table"}). A brief summary of each disorder is provided below, highlighting important features both shared and distinct among the 3 syndromes. [Table 3](#T3){ref-type="table"} reviews the differential diagnosis of disorders with overlapping signs and symptoms.

###### 

Compilation of previously published diagnostic criteria for AHC, RDP, and CAPOS syndromes
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###### 

Major and minor features supporting *ATP1A3* molecular analysis
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###### 

Differential diagnosis of *ATP1A3*-related disorders and molecular etiology
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Classic AHC. {#s1-1}
------------

Since the discovery of *ATP1A3* as the causative mutation in the majority of AHC cases,^[@R5],[@R6]^ at least 34 unique mutations have been identified.^[@R14]^ AHC is characterized by recurrent episodes of paroxysmal hemiplegia, dystonia, ocular movement abnormalities (monocular nystagmus and deviation), autonomic dysfunction, as well as developmental delay. With increasing age, many patients ultimately manifest epilepsy; however, the characteristic presentation in infants includes a variety of episodic, nonepileptic tonic, dystonic, or plegic (weakness) spells that often are refractory to treatment with most therapeutic agents. The early onset and rapidly evolving clinical signs and symptoms frequently contribute to diagnostic delays. The relatively broad differential diagnosis ([table 3](#T3){ref-type="table"}) and the lack of a specific genetic test prior to 2012 resulted in a widely variable approach to attempts to treat paroxysmal events (often presumed to be seizures even in the absence of electrophysiologic evidence). While the most pathognomonic events include hemiplegic or hemidystonic episodes that affect either side of the body, children also frequently have bilateral involvement, including generalized fluctuating dystonia, quadriplegia, or paresis of variable duration.

A variety of nonparoxysmal symptoms and signs become increasingly evident with age, including global developmental delays; behavioral, attentional, and executive dysfunction with variable intellectual disability; dysarthria, ataxia, chorea, dystonia, and, less frequently, pyramidal tract signs such as spasticity and hyperreflexia. To date, we have limited data on the full spectrum of the burden of acquired neurologic deficits in this population; more robust longitudinal data are needed.

Rapid-onset dystonia parkinsonism. {#s1-2}
----------------------------------

In 2004, it was demonstrated that heterozygous mutations in the *ATP1A3* gene are causative of RDP.^[@R4]^ Since then, at least 14 mutations have been identified.^[@R4],[@R9],[@R15][@R16][@R19]^ Clinical hallmarks of RDP include the abrupt onset of bulbar symptoms and limb dystonia with features of parkinsonism (bradykinesia and postural instability) that exhibit limited progression over weeks and little change thereafter. Dystonic symptoms typically show minimal response to [l]{.smallcaps}-dopa or dopaminergic agonists. The severity of acquired neurologic signs and symptoms demonstrates a rostrocaudal gradient of involvement (face \> arm \> leg). Disease onset has been reported between the ages of 4 and 58 years. Symptoms can be triggered by a broad range of physical, emotional, or chemical triggers. Beyond dystonia and parkinsonism, several patients with classic RDP display other symptoms including depression and anxiety/social phobia. A minority of patients develop seizures years after the disease onset. The diagnostic criteria for RDP were revised in 2007.^[@R20]^ Major and minor diagnostic criteria for RDP are summarized in [table 1](#T1){ref-type="table"}.

CAPOS syndrome. {#s1-3}
---------------

The constellation of CAPOS was first described as a unique clinical entity in 1996.^[@R3]^ To date, very few patients have been described with this syndrome and no information about prevalence and incidence is available. The combination of the aforementioned symptoms is characteristic of this syndrome, although these do not constitute diagnostic criteria, given the limited number of cases. A single recurrent missense mutation in *ATP1A3* (c.2452G\>A;Glu818Lys) has been identified in all cases to date.^[@R21]^ Of note, only 5 of 18 identified patients exhibit pes cavus, and a full spectrum of manifestations is likely broader.^[@R7],[@R21][@R22][@R23]^

The identification of an increasing number of patients with mutations in the *ATP1A3* gene and phenotypic overlap of the above-mentioned diseases demonstrates that classic AHC, classic RDP, and CAPOS syndrome constitute clinical prototypes of a continuous phenotypic spectrum from *ATP1A3*-related disorders.^[@R24]^

Updating the current syndrome-based diagnostic algorithm using criteria outlined in [table 1](#T1){ref-type="table"}, with one emphasizing the presence of the key major (pathognomonic) and minor (supporting) signs and symptoms ([table 2](#T2){ref-type="table"}), is intended to focus attention on the rapidly evolving spectrum of *ATP1A3*-related disorders for clinicians and families. Ideally, this dual approach will facilitate the earliest possible identification of the primary genetic defect in patients presenting a wider phenotypic spectrum. This will reduce the often prolonged diagnostic odyssey and facilitate prospective enrollment into clinical studies designed to help better understand the natural history of the disorder.

STANDARDIZED DEFINITIONS FOR PAROXYSMAL EVENTS IN AHC {#s2}
=====================================================

The complex and variable paroxysmal events in AHC result in challenges in defining aspects of the *ATP1A3*-related disorders. Currently, neither families nor clinicians use a unified set of definitions to guide them when they attempt to communicate the frequency, duration, and overall effect of types of episodes their child may be experiencing. It is often not clear to families or their clinicians how they should categorize episodes that may or may not be seizures or some other complex movement disorders. Not only does this result in an inconsistent approach among both caregivers and clinicians, it makes it more challenging for parents to determine what constitutes an emergency for which they should seek additional urgent medical assistance. [Table 4](#T4){ref-type="table"} presents a simplified nomenclature using a language more accessible for caregivers to document events in a way that might be valuable in the context of longitudinal studies or clinical trials.

###### 

Proposed nomenclature for simplified episode description in alternating hemiplegia of childhood
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CATASTROPHIC EVENTS IN *ATP1A3*-RELATED DISORDERS {#s3}
=================================================

Over the course of the past 2 decades, 4 of 187 (2%) prospectively enrolled patients in the US/International AHCF registry with documented pathogenic mutations in *ATP1A3* and clinical features consistent with AHC have died, many of them unexpectedly, with or without an apparent antecedent stressor. Three scenarios have emerged that deserve additional attention in terms of focused research, prevention strategies, and clinical management recommendations: (1) the sudden acquisition of newly acquired, nonparoxysmal severely disabling neurologic deficits, representing a substantial lasting change in the neurologic status in a previously stable patient, (2) the appearance of increasingly refractory epilepsy or bilateral dystonia and status epilepticus or status dystonicus, and (3) sudden unexpected death, with or without an obvious antecedent stressor. Admittedly, the literature regarding these scenarios, as well as potential causes and/or interventions, is essentially nonexistent. [Table 5](#T5){ref-type="table"} lists age, *ATP1A3* mutation, associated clinical features, perimortem circumstances, and systemic pathology data for the 4 patients with AHC.

###### 

*ATP1A3* mutation, associated clinical features, perimortem circumstances, and systemic pathology data in 4 deceased patients with AHC
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The sudden acquisition of new and severely disabling neurologic deficits in patients with AHC, particularly dystonia, has many parallels with the acute or subacute acquisition of evolving neurologic deficits initially described in patients with RDP.^[@R20]^ However, in patients with AHC, these deficits occur in the context of an already established syndrome of paroxysmal AHC symptoms and neurodevelopmental deficits, making it initially less obvious that any episode may ultimately prove irreversible. Our understanding of the critical trigger(s) for such irreversible transformations remains unclear, since antecedent events often appear no different from hundreds of prior episodes these children may have already experienced.

Sudden unexpected death in epilepsy (SUDEP) has demanded increasing attention on the part of families and practitioners within the epilepsy community and is the leading cause of death in the absence of status epilepticus or seizure-related trauma.^[@R25]^ A widely accepted definition for SUDEP is included in table e-1 at [Neurology.org/ng](10.1212/NXG.0000000000000139).^[@R26]^ Proposed risk factors include the use of multiple anticonvulsants, poor medication compliance, uncontrolled seizures, and the presence of additional neurologic deficits, in addition to epilepsy, among others.^[@R27]^

In light of the heightened awareness that certain molecular etiologies may predispose to an increased risk of sudden death,^[@R28]^ it should be emphasized that *ATP1A3*-related disorders may have a similar association, both in the presence and absence of comorbid epilepsy. *ATP1A3* is expressed in human cardiac tissue,^[@R29]^ and faulty cardiac repolarization has been demonstrated in patients with AHC.^[@R30]^ Repetitive brief asystole was documented in an individual with a confirmed *ATP1A3* mutation and AHC.^[@R31]^ Finally, as illustrated in [table 5](#T5){ref-type="table"}, 3 patients prospectively enrolled in the AHCF registry who died suddenly had documented evidence of cardiac structural abnormalities, including ventricular hypertrophy, on autopsy studies. In trying to understand and prevent sudden death in *ATP1A3*-related neurologic disorders, it is important to create appropriate evidence-based recommendations regarding initial evaluation and long-term monitoring of cardiac status.

CRITICAL GAPS IN OUR CURRENT KNOWLEDGE OF *ATP1A3*-RELATED DISORDERS {#s4}
====================================================================

Children who present acutely with dystonia, encephalopathy, or ataxia in the absence of pathognomonic features of classic AHC (i.e., alternating weakness or dystonia) account for an increasing proportion of *ATP1A3* mutation--positive cases. The prognosis for children with variants of uncertain significance or for those who have a variant with known low frequency is uncertain, resulting in increased concern for both parents and clinicians.

Even in patients with AHC presenting with a classic classic presentation in the context of one of the common mutations, we have very limited information on long-term outcome with these disorders. This is due to (1) lack of rigorous longitudinal natural history follow-up, (2) the relatively recent identification of the primary genetic defect in AHC and CAPOS, (3) delays in clinical awareness/implementation of molecular testing, and (4) the enormous variability of episodes and the absence of standardized measurement tools. The development of such tools is critical in quantifying disease burden and ideally would allow us to accurately represent episode type, frequency, and severity and the subsequent influence on cognition, mood and behavior, language, bulbar function, gross and fine motor function, activities of daily living, and quality of life.

Disease progression in subsets of *ATP1A3*-related disorders associated with fluctuating neurologic signs and symptoms is often hard to appreciate, in that symptoms follow a waxing/waning course that may result in increasing difficulty (and parental fatigue) in complying with routine clinic visits. Children may gradually fall behind in development relative to their peers, or repeatedly lose then regain skills, making acquired accumulated and progressive neurologic deficits not immediately obvious. As children get older, caregivers often become increasingly reluctant to use the urgent care setting when new events occur because knowledge and tools are ineffective and lasting solutions to understand and manage these complex events are not yet available.

Over time, documenting the frequency and course of events may seem overwhelming and futile to primary caregivers. Physicians, likewise, become discouraged when imaging tests, EEGs, and laboratory testing repeatedly fail to provide answers or guidance for management. As an example, when a new type of paroxysmal event appears, it may initially be considered a variation of a previously documented complex nonepileptic movement disorder rather than a possible seizure. Appropriate intervention may, thus, be delayed when overt seizures finally manifest, resulting in potentially catastrophic outcomes such as death or acquisition of new permanent neurologic deficits in the setting of status epilepticus.

There may be important variations in phenotypic severity among patients with the most common *ATP1A3* mutations affecting "hot spots" in exons 17, 18, and 21.^[@R9]^ Initial data from patients with AHC with an E815K mutation demonstrated more severe impairment in motor function, intellectual disability, and epilepsy.^[@R14],[@R32]^ Moving forward, development of standardized multicenter databases would allow rigorous monitoring, and documentation of clinical disease evolution should help permit us to more accurately capture mutation-specific differences with prognostic implications.

In many disorders, tools such as motor function scales, timed tests, and neuropsychological tools, including age-appropriate assessments of executive and cognitive function, mood, and behavior, can be standardized for use across patient cohorts. Unfortunately, the fluctuating nature of AHC symptoms in many children makes standardized motor and cognitive function tests more challenging to use than in other more static or progressive neurologic disorders. Therefore, a focus on caregiver-reported outcomes or a measure of overall functional assessment of patients in performing daily self-care tasks may be more practical in this setting.

SUGGESTED ACUTE MANAGEMENT RECOMMENDATIONS FOR COMMONLY ENCOUNTERED ADVERSE EVENTS IN PATIENTS WITH *ATP1A3*-RELATED DISORDERS {#s5}
==============================================================================================================================

During the workshop, members attempted to identify the most common and challenging clinical scenarios encountered in the acute care setting. As yet, these issues are largely underaddressed in the existing literature. It was agreed that action plans for certain commonly encountered issues could help standardize approaches in the acute setting. These recommendations could be an invaluable tool to facilitate communication between primary caregivers and physicians when they seek urgent care for their child with an *ATP1A3*-related neurologic disorder. They may help streamline discussions with health care providers and minimize the risk of adverse complications. We have created initial drafts for action recommendations (see supplemental materials) to address 3 recurring clinical scenarios frequently involving affected children or adults: (1) increasingly frequent and painful dystonic crises or status dystonicus, (2) new signs or symptoms thought to be clinically consistent with epilepsy or status epilepticus, and (3) recurring behavioral crises constituting a danger to self or others.

RECOMMENDATIONS FOR MOLECULAR DIAGNOSTIC TESTING {#s6}
================================================

Both AHC and RDP phenotypes can be associated with de novo mutations or dominant inheritance within families, although the vast majority of patients with AHC identified to date have de novo mutations. Because neurologic symptoms and signs associated with *ATP1A3*-related disorders overlap with many other neurologic syndromes, the *ATP1A3* gene has been increasingly included in next-generation sequencing (NGS) panels for epilepsy, ataxia, and dystonia/parkinsonism. Patients identified by NGS techniques account for a growing percentage of newly identified patients, whose signs and symptoms may or may not fit within the spectrum of previously described phenotypes for AHC and RDP.

Despite the important observation that mutations in the *ATP1A3* gene are a frequent cause of both AHC and RDP, some individuals who meet clinical diagnostic criteria for these syndromes will not have evident pathogenic mutations in *ATP1A3*. Studies continue to identify alternate molecular etiologies in patients with well-defined AHC and RDP phenotypes and for potentially valuable biomarkers that can distinguish between patients with or without pathogenic mutations in *ATP1A3*. If AHC is suspected clinically and an *ATP1A3* mutation cannot be identified, consideration could be given to then sequence individual genes or NGS panels that include complete coverage for genes associated with overlapping neurologic phenotypes ([table 3](#T3){ref-type="table"}).

A medical genetics consultation is strongly recommended before pursuing whole-exome sequencing (WES), a complex test with the potential for incidental findings that requires detailed pretest and posttest counseling. When a diagnosis of AHC or RDP is not previously suspected by the clinician, extra caution should be used in the interpretation of previously unreported or rare pathogenic mutations or variants of unknown significance (VUSs), with care taken to evaluate both the specific mutation and the symptoms of the patient for proper diagnosis along the spectrum of *ATP1A3*-related disorders. Caution is warranted because VUSs are very common in panel testing and extremely common in WES. Consultation with a medical genetics professional familiar with the evaluation of a VUS and with family studies can aid in results interpretation, testing of family members, and genetic counseling.

*ATP1A3*-RELATED DISORDERS AND EPILEPSY {#s7}
=======================================

Approximately 50% of children with AHC also carry a diagnosis of epilepsy,^[@R32][@R33][@R34]^ although the certainty of this diagnosis can remain elusive because of similarity of epileptic and nonepileptic paroxysmal events such as dystonia, tremor, or paresis. By contrast, patients with RDP have seizures as a rare comorbidity,^[@R20]^ although this manifestation may be underrecognized as the number of patients with RDP is far less than AHC.

Recently, the International League Against Epilepsy revised the Operational Clinical Definition of Epilepsy to allow for the diagnosis of epilepsy following a first seizure in the context of increased recurrence risk.^[@R35]^ The challenge in accurately assessing the recurrence risk in adults and children with *ATP1A3*-related disorders is significant and may ultimately be dependent on specific genetic mutations.

Reviews of *ATP1A3*-related disorders have emphasized the potentially catastrophic course of epilepsy in patients with AHC.^[@R32]^ For this reason, we attempted to more precisely address seizure and epilepsy-related clinical practice issues. It was agreed that, when feasible, video-EEG characterization should be obtained when new, distinct, and stereotyped events are noted. However, the abundance and variability of paroxysmal events in AHC makes video-EEG characterization impractical for some instances. Broad input from family members, caretakers, and other medical personnel, as well as the use of personal video capabilities, may aid in more accurately characterizing the events in question.

Routine EEG may provide limited benefit early in the course of AHC evolution because classic epileptiform features are absent during most episodes.^[@R33]^ It is unknown whether EEG may help to better assess further risk of seizure later in the course of the disorder, when epilepsy is more typically present. Ultimately, workshop participants agreed that if clinical suspicion is high and EEG features suggestive of an underlying seizure tendency are noted, initiation of an anticonvulsant medication is warranted. If the EEG is unrevealing, then further clinical assessment and video-EEG monitoring is reasonable.

DISCUSSION AND FUTURE DIRECTIONS {#s8}
================================

*ATP1A3*-related disorders have become increasingly recognized with the advent of more potent molecular diagnostic tools. However, substantial knowledge gaps remain in understanding how specific genetic mutations and other epigenetic phenomena might influence physiologic mechanisms to produce the variable phenotypes. There is no specific treatment for *ATP1A3*-related diseases other than symptomatic, although flunarizine is widely used.^[@R36],[@R37]^ There is no approved medication or device that alters the underlying deficit in the Na^+^/K^+^ pump.

During the course of workshop proceedings, it became clear that considerable challenges remain. A critical impediment to effective clinical trial design is a lack of standardized language to capture and measure disease burden for paroxysmal symptoms in AHC. Clinical trial designs typically implemented in epilepsy are inadequate. Patients with *ATP1A3*-related disorders also demonstrate variable impairments in cognition, language, mood, behavior, and gross motor and fine motor functions, and these outcomes will also be important to effectively document and assess reliably over time. Finally, development or use of caregiver and patient-reported outcome tools will likely prove a critical part of this process, especially if broader quality of life trends can be incorporated in addition to typical event counting. This combination may in the end prove the most effective way to measure improvement in response to specific targeted interventions. Given the variable phenotype, a multifaceted approach will be needed in which outcome measures are carefully chosen to reflect the most likely benefit of any intervention.
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AHC

:   alternating hemiplegia of childhood

AHCF

:   Alternating Hemiplegia of Childhood Foundation

CAPOS

:   cerebellar ataxia, areflexia, pes cavus, optic atrophy, and sensorineural hearing loss

NGS

:   next-generation sequencing

RDP

:   rapid-onset dystonia parkinsonism

SUDEP

:   sudden unexpected death in epilepsy

WES

:   whole-exome sequencing
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